Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes

Next Previous
Trial Profile

Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms Ellipse
  • Sponsors Novo Nordisk

Most Recent Events

  • 25 Sep 2020 Results of post hoc analysis assessing weight-related parameters presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
  • 04 Sep 2020 Results of post hoc analysis evaluating effect of liraglutide treatment on weight parameters in children and adolescents with type 2 diabetes, presented at the 2020 European and International Congress on Obesity
  • 28 Jun 2019 According to an European Medicines Agency media release, the EMA's human medicines committee (CHMP) has recommended granting an extension of indication to Victoza (liraglutide) to include the treatment of children and adolescents aged 10 years or older with type 2 diabetes. The CHMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top